Official ESCRS | European Society of Cataract & Refractive Surgeons

1 year results after the Implantation of the Microstent Cypass

Session Details

Session Title: Special Cases
Session Date/Time: Friday 20/02/2015 | 08:30-10:30
Paper Time: 09:04
Venue: Sadirvan B
First Author: : M.Rau GERMANY
Co Author(s): :                  

Abstract Details


To evaluate the safety and clinical outcomes of an ab interno supraciliary implant (CyPass Micro-Stent, Transcend Medical, Inc., Menlo Park, CA, USA) in patients with open-angle glaucoma (OAG) undergoing cataract surgery or as a standalone procedure


Augenklinik Cham, Germany


Eyes (n=33) were enrolled in a single site (Cham, Germany) by the investigator. The majority of the eyes (n=24) were undergoing concomitant cataract surgery. In those cases, the supraciliary device was implanted immediately following the cataract surgery portion of the procedure through the same corneal incision using an ab interno approach. Medications were stopped following the procedure and re-introduced at the investigator’s discretion, depending on the intraocular pressure (IOP) target of the patient. Main outcomes were adverse events, IOP changes, and number of IOP-lowering medications.


At baseline, subjects had a mean IOP of 23.3 ± 6.8 mmHg and were taking a mean of 1.9 ± 1.1 IOP-lowering medications. All implants were placed successfully, and no major sight threatening adverse events occurred. There was 1 case (4.2%) of transient hypotony (IOP < 6 mmHg) resolving within 1 month, and 1 case where the device was re positioned in a subsequent procedure (4.2%). At month 12, subjects (n=22) had a mean IOP of 14.6 ± 4.3 mmHg, representing a paired 28% reduction, with mean medication usage reduced to 0.7 ± 1.0.


Implantation of the CyPass Micro-Stent in combination with cataract surgery or as a standalone procedure reliably results in minimal complications and reduction of IOP and IOP-lowering medications at 12 months postoperatively.

Financial Disclosure:

One or more of the authors travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous